Logo image of BBLG

BONE BIOLOGICS CORP (BBLG) Stock Fundamental Analysis

USA - NASDAQ:BBLG - US0980706008 - Common Stock

2.14 USD
+0.08 (+3.88%)
Last: 9/16/2025, 8:00:01 PM
2.14 USD
0 (0%)
After Hours: 9/16/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BBLG. BBLG was compared to 540 industry peers in the Biotechnology industry. While BBLG has a great health rating, there are worries on its profitability. BBLG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BBLG has reported negative net income.
BBLG had a negative operating cash flow in the past year.
In the past 5 years BBLG always reported negative net income.
BBLG had a negative operating cash flow in each of the past 5 years.
BBLG Yearly Net Income VS EBIT VS OCF VS FCFBBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -106.15%, BBLG is doing worse than 77.22% of the companies in the same industry.
The Return On Equity of BBLG (-112.68%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -106.15%
ROE -112.68%
ROIC N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBLG Yearly ROA, ROE, ROICBBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K -10K

1.3 Margins

BBLG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBLG Yearly Profit, Operating, Gross MarginsBBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for BBLG has been increased compared to 1 year ago.
Compared to 5 years ago, BBLG has more shares outstanding
There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BBLG Yearly Shares OutstandingBBLG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
BBLG Yearly Total Debt VS Total AssetsBBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -12.76, we must say that BBLG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -12.76, BBLG is doing worse than 77.04% of the companies in the same industry.
There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.76
ROIC/WACCN/A
WACCN/A
BBLG Yearly LT Debt VS Equity VS FCFBBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

BBLG has a Current Ratio of 17.24. This indicates that BBLG is financially healthy and has no problem in meeting its short term obligations.
BBLG's Current ratio of 17.24 is amongst the best of the industry. BBLG outperforms 92.96% of its industry peers.
BBLG has a Quick Ratio of 17.24. This indicates that BBLG is financially healthy and has no problem in meeting its short term obligations.
BBLG has a better Quick ratio (17.24) than 92.96% of its industry peers.
Industry RankSector Rank
Current Ratio 17.24
Quick Ratio 17.24
BBLG Yearly Current Assets VS Current LiabilitesBBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

BBLG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.21%, which is quite impressive.
EPS 1Y (TTM)62.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BBLG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.50% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y86.23%
EPS Next 2Y36.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BBLG Yearly EPS VS EstimatesBBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BBLG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBLG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBLG Price Earnings VS Forward Price EarningsBBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBLG Per share dataBBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

BBLG's earnings are expected to grow with 36.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.5%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BBLG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BONE BIOLOGICS CORP

NASDAQ:BBLG (9/16/2025, 8:00:01 PM)

After market: 2.14 0 (0%)

2.14

+0.08 (+3.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners0.37%
Inst Owner Change-98.25%
Ins Owners0.04%
Ins Owner Change0%
Market Cap3.85M
Analysts82.86
Price Target22.95 (972.43%)
Short Float %0.47%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-45.09%
Min EPS beat(2)-124.81%
Max EPS beat(2)34.64%
EPS beat(4)2
Avg EPS beat(4)-92.51%
Min EPS beat(4)-287.25%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)-12.14%
EPS beat(12)9
Avg EPS beat(12)-17.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)36.36%
EPS NQ rev (1m)-132.07%
EPS NQ rev (3m)31.67%
EPS NY rev (1m)-108.29%
EPS NY rev (3m)-229.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 0.58
EV/EBITDA N/A
EPS(TTM)-21.15
EYN/A
EPS(NY)-4.07
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0
BVpS3.66
TBVpS3.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.15%
ROE -112.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.24
Quick Ratio 17.24
Altman-Z -12.76
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.92%
EPS Next Y86.23%
EPS Next 2Y36.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.83%
OCF growth 3YN/A
OCF growth 5YN/A